Jon Behr joined the T1D fund at its inception as a Managing Director.
Prior to the T1D Fund, Jon was a Market Sector Leader and Executive in Residence at Partners Healthcare Innovation, leading a team responsible for driving technology translation from research hospitals affiliated with Harvard Medical School. Before Partners, Jon held senior venture creation roles, including Principal at PureTech Ventures (PRTC) and Vice President of New Ventures for Enlight Biosciences. In those roles Jon co-founded and supported seven companies and took senior operating roles in several. He is currently a board observer for Diasome, Enthera, ImmusanT, and Inversago and Pandion and was previously a board observer or director of companies including Provention Bio (PRVB), Semma Therapeutics, AntolRx, Exosome Diagnostics, and Entrega Inc.
Jon has a Ph.D. in Biological Engineering from Massachusetts Institute of Technology as a Howard Hughes Medical Institute fellow, and received his B.S. in Bioengineering summa cum laude as phi-beta-kappa co-valedictorian from Rice University.